It wasn't the perfect second quarter, but we'll take it. You'll recall, U.S. investments in private companies tracked by BioWorld in the first quarter of the year started off like gangbusters, more than doubling the funding in the year-ago quarter. IPOs, on the other hand, left something to be desired.
The hemophilia drug market is well established with multiple drugs designed to replace the underlying deficiency: factor VIII for hemophilia A and factor IX for hemophilia B.
Those forward-looking disclosures management reads at the beginning of presentations and the risk factors listed in their SEC filings are often viewed by investors as standard lawyer-speak to cover the company from potential lawsuits should something bad happen.
Investors wanting to buy into the high-growth biotech industry without purchasing shares of individual companies have had limited choices of exchange traded funds (ETFs).
"Personalized medicine," "precision medicine," "pharmacogenomics" or whatever you want to call it, it's pretty clear the industry is moving in the direction of having drugs to treat patients based on their genetic makeup.
Biotechs often set up subsidiaries to house assets for tax reasons or to house programs unrelated to their core mission that might get spun off, but Moderna Therapeutics Inc. has a new twist, establishing "venture companies" focused on specific diseases.
Through the first four months of the year, BioWorld Snapshots tracked 24 IPOs by drug companies on U.S. and international exchanges compared to 36 in the same time period last year.
As with any new technology, it takes baby steps to get drugs through the regulatory process and onto the market. And nanomedince is no exception. The technology is certainly progressing, but at a methodical pace.
As with any new technology, it takes baby steps to get drugs through the regulatory process and onto the market. And nanomedince is no exception. The technology is certainly progressing, but at a methodical pace.
In spite of increased biotech valuations providing for access to capital through the equity markets, the market for capital from the sale of royalties and structured debt tied to product sales is as hot as it's ever been.
